{"id":3914,"date":"2025-03-31T18:11:52","date_gmt":"2025-03-31T18:11:52","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/dihydrocodeine-tartate-txt\/"},"modified":"2025-03-31T18:11:52","modified_gmt":"2025-03-31T18:11:52","slug":"dihydrocodeine-tartate-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/dihydrocodeine-tartate-txt\/","title":{"rendered":"Dihydrocodeine tartate.txt"},"content":{"rendered":"

Dihydrocodeine tartate<\/h1>\n

CLINICAL USE <\/H3>
\nSupraventricular arrhythmias Heart failure

DOSE IN NORMAL RENAL FUNCTION <\/H3>Digitalisation: 1\u20131.5 mg in divided doses over 24 hours, followed by 62.5\u2013500 mcg daily, adjusted according to responseEmergency loading (IV): 0.75\u20131 mg over at least 2 hours

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :780.9<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :25<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 50\u201375<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :5\u20138<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :30\u201340\/100

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : 125\u2013250 micrograms per day
  • 10 to 20 &nbsp &nbsp : 125\u2013250 micrograms per day. Monitor levels
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose commonly 62.5 micrograms alternate days, or 62.5 micrograms daily. Monitor levels

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsAngiotensin-II antagonists: concentration increased by telmisartanAnti-arrhythmics: concentration increased by amiodarone and propafenone (half maintenance dose of digoxin)Antidepressants: concentration reduced by St John\u2019s wort \u2013 avoid concomitant useAntifungals: increased toxicity if hypokalaemia occurs with amphotericin; concentration increased by itraconazoleAntimalarials: concentration possibly increased by quinine, hydroxychloroquine and chloroquine; increased risk of bradycardia with mefloquineCalcium-channel blockers: concentration increased by diltiazem, lercanidipine, nicardipine, verapamil and possibly nifedipine; increased risk of AV block and bradycardia with verapamilCiclosporin: concentration increased by ciclosporinDiuretics: increased toxicity if hypokalaemia occurs; concentration increased by spironolactone

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral, IV

    Rate of Administration <\/H4>Loading dose: infuse over
  • 10 to 20 &nbsp &nbsp : minutes

    Comments<\/H4>IV administration: dilute dose to 4 times volume with sodium chloride 0.9% or glucose 5%IV dosing may be used for very rapid control

    OTHER INFORMATION <\/H4>Complex kinetics in renal impairment: Volume of distribution and total body clearance reduced in CKD 5Steady-state plasma monitoring advisable: normal range 0.8\u20132 nanograms\/mL; take at least 8 hours post-dose, ideally before dose in the morningIf changing from oral to IV reduce dose by a thirdHypokalaemia, hypomagnesaemia, marked hypercalcaemia and hypothyroidism increase toxicityIncreases uraemic gastrointestinal symptomsOnly 3% of dose is removed after a 5 hour\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : sessionConcomitant administration of phosphate binders reduces GI absorption by up to 25%Digitalisation using 750 micrograms \u2013 1 mg. Interval between normal or reduced doses may need to be lengthened.
    \n","protected":false},"excerpt":{"rendered":"

    Dihydrocodeine tartate CLINICAL USE Supraventricular arrhythmias Heart failure DOSE IN<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3914","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3914"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3914\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}